ScholarIQanswers from OpenAlex & ORCID
John Radford
ResearcherPublications, citations & collaboration network
John Radford is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does John Radford have?
ScholarIQindexed works
John Radford has 685 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does John Radford have?
ScholarIQcitation count
John Radford has 30,105 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of John Radford?
ScholarIQh-index
John Radford has an h-index of 88 in OpenAlex.
What is the i10-index of John Radford?
ScholarIQi10-index
John Radford has an i10-index of 276 in OpenAlex.
What is the ORCID of John Radford?
ScholarIQorcid
The ORCID for John Radford is on the source record.
What is the OpenAlex record for John Radford?
ScholarIQopenalex
The OpenAlex for John Radford is on the source record.
What are the most-cited papers on John Radford?
ScholarIQmost cited works
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson, Massimo Federico, Amy A. Kirkwood, Alexander Fosså, Leanne Berkahn, Angelo Michele Carella, Francesco d’Amore, Gunilla Enblad, Antonella Franceschetto, Michael Fulham, Stefano Luminari, Michael O'Doherty, Pip Patrick, Thomas A. Roberts, Gamal Sidra, Lindsey Stevens, Paul Smith, Judith Trotman, Zaid Viney, John Radford, Sally F. Barrington
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Sally F. Barrington, Amy A. Kirkwood, Antonella Franceschetto, Michael Fulham, Thomas H. Roberts, Helén Almquist, Eva Brun, Karin Hjorthaug, Zaid Viney, Lucy Pike, Massimo Federico, Stefano Luminari, John Radford, Judith Trotman, Alexander Fosså, Leanne Berkahn, Daniel Molin, Francesco d’Amore, Donald A. R. Sinclair, Paul Smith, Michael O’Doherty, Lindsey Stevens, Peter Johnson
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Judith Trotman, Sally F. Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter Fingerle‐Rowson, Jiawen Zhu, Tina Nielsen, Deniz Şahin, Wolfgang Hiddemann, Robert Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine S. Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van Eygen, Randeep Sangha, Pam McKay, Jonathan Wilson, Richard van der Jagt, Daryl Roitman, Marek Trněný, Jiřı́ Mayer, Katell Le Dû, Philippe Solal‐Céligny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange‐Krex, Axel Florschütz, Hans‐Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Heß, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling‐Kaiser, Martin Hoffmann, Zita Borbényi, M. Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Párraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, José Antonio Márquez Navarro, Carlos Grande García, Herman Nilsson‐Ehle, Helen O. McCarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin J.S. Dyer, Ruth Pettengell, John Seymour, John G. Gribben, Saad Al‐Ismail, F. N. Al‐Refaie, Norbert Blesing, Christopher Macnamara, Ann O’Callaghan, Andrew Haynes, George Follows, Roderick J. Johnson, David Cunningham, Kristian M. Bowles, Graham P. Collins, Eve Gallop‐Evans, Stephen Robinson, Chezhian Subash